SAHPRA reported deficiencies including: Inadequate sterile manufacturing conditions Insufficient equipment for aseptic preparation Lack of appropriate air filtration and environmental controls Increased risk of contamination Contaminated injectable products may lead to serious infections and other complications
This discovery provides an essential mechanistic blueprint to explain why patient responses vary, why weight loss eventually plateaus, and how combining treatments could extend drug efficacy
The only FDA-approved treatments (disulfiram, naltrexone, and acamprosate) have been modestly successful in treating AUD (e.g., naltrexone reduces relapse rates by 5%) (for a detailed review and meta-analysis 1,2 ), but still are severely under-prescribed
There have now been many studies and analyses that suggest that the use of GLP-1 drugs goes beyond just weight loss and diabetes, with potential benefits ranging from helping mental illness and substance abuse to kidney disease, heart disease and even osteoarthritis, some experts say
October 10, 2021
But berberines glucose-lowering is glucose-dependent, meaning it tends to work harder under hyperglycemic conditions